Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metastatic Pancreatic Cancer

32 trials tracked for Metastatic Pancreatic Cancer: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 164 citations.

32Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 23 Phase 1 4 Other / NA 2
  1. Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 164 cited
  2. Phase 3 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed
  3. Phase 3 Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer Completed
  4. Phase 2 RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer Completed
  5. Phase 2 Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB) Completed
  6. Phase 2 FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine Completed
Show 26 more trials
  1. Phase 2 ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer Completed
  2. Phase 2 A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Completed
  3. Phase 2 A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Completed
  4. Phase 2 Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Completed
  5. Phase 2 ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer Completed
  6. Phase 2 Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer Completed
  7. Phase 2 Niraparib + Dostarlimab + RT in Pancreatic Cancer Completed
  8. Phase 2 Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer Completed
  9. Phase 2 Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer Completed
  10. Phase 2 A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer Completed
  11. Phase 2 Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Completed
  12. Phase 2 Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas Completed
  13. Phase 2 QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer Completed
  14. Phase 2 APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer Completed
  15. Phase 2 A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer Completed
  16. Phase 2 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Completed
  17. Phase 2 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Completed
  18. Phase 2 Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer Completed
  19. Phase 2 First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem Completed
  20. Phase 2 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Completed
  21. Phase 1 BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study Completed
  22. Phase 1 A Study to Investigate 14C-bemcentinib in Healthy Male Subjects Completed
  23. Phase 1 Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer Completed
  24. Phase 1 A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema Completed
  25. N/A Improving Informed Consent for Palliative Chemotherapy Completed
  26. N/A EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Metastatic Pancreatic Cancer: what the trials found

Albumin-bound paclitaxel (ABI-007) demonstrated statistically significant improvements in overall survival (OS), progression-free survival (PFS) by independent radiological review, and objective response rate compared to standard treatment 4.

FOLFIRINOX showed a 41% rate of patients alive and without radiological or clinical progression at 6 months post-randomization 7. Folfirinox was also evaluated in a separate established trial 21.

AMG 479 was evaluated in both Phase 2 6 and Phase 3 trials 2.

Recent results — preliminary, needs further review

  • Nab-Paclitaxel is currently under investigation in a Phase 2 trial 1.
  • ABT-888 is being evaluated in a Phase 2 study 5.

For the clinician treating this condition

  • Albumin-bound paclitaxel (ABI-007) provides statistically significant improvements in OS, PFS, and objective response rates 4.
  • FOLFIRINOX shows clinical activity with 41% of patients remaining progression-free at 6 months 7.

AI synthesis of 7 cited trials, updated Aug 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Daraxonrasib improves overall survival to 13.2 months in mPDAC patients compared to 6.7 months
Oncology RCT
Daraxonrasib improves overall survival to 13.2 months in mPDAC patients compared to 6.7 months Trial shows daraxonrasib improves survival for pancreatic cancer patients
This Phase 3 randomized trial of 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma found daraxonrasib signifi…
A Phase 3 trial found that daraxonrasib significantly extended survival times for patients with specific types of metastatic pancreatic canc…
Jul 26, 2026